|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
IL166241A0
(en)
|
2002-07-29 |
2006-01-15 |
Rigel Pharmaceuticals Inc |
Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
|
|
ES2421139T3
(es)
|
2003-07-30 |
2013-08-29 |
Rigel Pharmaceuticals, Inc. |
Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
|
|
AU2011253635B2
(en)
*
|
2003-09-17 |
2014-10-30 |
Janssen Pharmaceutica, N.V. |
Fused heterocyclic compounds
|
|
SG146683A1
(en)
|
2003-09-17 |
2008-10-30 |
Janssen Pharmaceutica Nv |
Fused heterocyclic compounds as serotonin receptor modulators
|
|
AU2004313947B2
(en)
*
|
2003-12-17 |
2011-03-31 |
Sgx Pharmaceuticals, Inc. |
Bicyclic pyrazolo-fused compounds as protein kinase modulators
|
|
WO2005123111A2
(en)
*
|
2004-06-21 |
2005-12-29 |
Exelixis, Inc. |
Maxs as modifiers of the axin pathway and methods of use
|
|
EP1805142A4
(en)
|
2004-09-23 |
2009-06-10 |
Reddy Us Therapeutics Inc |
PYRIDINE-BASED COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING SAME
|
|
US7449458B2
(en)
|
2005-01-19 |
2008-11-11 |
Rigel Pharmaceuticals, Inc. |
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
|
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
WO2006133426A2
(en)
|
2005-06-08 |
2006-12-14 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
WO2007098507A2
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
US8969295B2
(en)
*
|
2006-04-14 |
2015-03-03 |
Massachusetts Institute Of Technology |
Identifying and modulating molecular pathways that mediate nervous system plasticity
|
|
CA2657227A1
(en)
*
|
2006-07-14 |
2008-01-17 |
Novartis Ag |
Pyrimidine derivatives as alk-5 inhibitors
|
|
KR20090082453A
(ko)
*
|
2006-11-01 |
2009-07-30 |
버텍스 파마슈티칼스 인코포레이티드 |
야누스 키나제의 억제제로서 유용한 트리사이클릭 헤테로아릴 화합물
|
|
JP2010526048A
(ja)
*
|
2007-05-04 |
2010-07-29 |
アストラゼネカ アクチボラグ |
アミノ−チアゾリル−ピリミジン誘導体、および癌の治療のための該誘導体の使用
|
|
HRP20170317T1
(hr)
|
2008-02-15 |
2017-04-21 |
Rigel Pharmaceuticals, Inc. |
Spojevi pirimidin-2-amina i njihova uporaba kao inhibitora jak kinaza
|
|
US8138339B2
(en)
|
2008-04-16 |
2012-03-20 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
|
US8063058B2
(en)
|
2008-04-16 |
2011-11-22 |
Portola Pharmaceuticals, Inc. |
Inhibitors of syk and JAK protein kinases
|
|
BRPI0910668A2
(pt)
|
2008-04-22 |
2019-09-24 |
Portola Pharmaceutiacals Inc |
inibidores de proteína quinases
|
|
US8309578B2
(en)
|
2008-11-25 |
2012-11-13 |
Nerviano Medical Sciences S.R.L. |
Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
|
|
EP2396004A4
(en)
*
|
2009-02-11 |
2012-07-25 |
Reaction Biology Corp |
SELECTIVE KINASE HEMMER
|
|
US8663210B2
(en)
|
2009-05-13 |
2014-03-04 |
Novian Health, Inc. |
Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
|
|
JO3030B1
(ar)
*
|
2009-06-26 |
2016-09-05 |
Galapagos Nv |
مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
|
|
US8435980B2
(en)
*
|
2009-07-15 |
2013-05-07 |
Abbvie Inc. |
Pyrrolopyridine inhibitors of kinases
|
|
MX337849B
(es)
*
|
2009-07-28 |
2016-03-09 |
Rigel Pharmaceuticals Inc |
Composiciones y metodos para inhibicion de la via jak.
|
|
SG178854A1
(en)
*
|
2009-08-28 |
2012-04-27 |
Array Biopharma Inc |
Raf inhibitor compounds and methods of use thereof
|
|
UY33213A
(es)
*
|
2010-02-18 |
2011-09-30 |
Almirall Sa |
Derivados de pirazol como inhibidores de jak
|
|
EP2975027A1
(en)
|
2010-11-01 |
2016-01-20 |
Portola Pharmaceuticals, Inc. |
Nicotinamides as jak kinase modulators
|
|
US9198911B2
(en)
|
2010-11-02 |
2015-12-01 |
The Trustees Of Columbia University In The City Of New York |
Methods for treating hair loss disorders
|
|
EP2782579B1
(en)
|
2011-11-23 |
2019-01-02 |
Portola Pharmaceuticals, Inc. |
Pyrazine kinase inhibitors
|
|
WO2013113762A1
(en)
|
2012-01-31 |
2013-08-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and kits for predicting the risk of having a cutaneous melanoma in a subject
|
|
DK2830662T3
(da)
*
|
2012-03-29 |
2019-01-02 |
Univ Columbia |
Fremgangsmåder til behandlng af hårtabsforstyrrelser
|
|
SG11201406584TA
(en)
|
2012-04-24 |
2014-11-27 |
Vertex Pharma |
Dna-pk inhibitors
|
|
WO2014013014A1
(en)
|
2012-07-18 |
2014-01-23 |
Fundació Privada Centre De Regulació Genòmica (Crg) |
Jak inhibitors for activation of epidermal stem cell populations
|
|
WO2014058921A2
(en)
|
2012-10-08 |
2014-04-17 |
Portola Pharmaceuticals, Inc. |
Substituted pyrimidinyl kinase inhibitors
|
|
RS62649B1
(sr)
|
2013-03-12 |
2021-12-31 |
Vertex Pharma |
Inhibitori dnk-pk
|
|
KR102411227B1
(ko)
|
2013-10-17 |
2022-06-21 |
버텍스 파마슈티칼스 인코포레이티드 |
Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정
|
|
MX358346B
(es)
*
|
2014-04-04 |
2018-08-15 |
Syros Pharmaceuticals Inc |
Inhibidores de la quinasa dependiente de ciclina 7 (cdk7).
|
|
WO2016109689A2
(en)
*
|
2014-12-30 |
2016-07-07 |
Novira Therapeutics, Inc. |
Derivatives and methods of treating hepatitis b infections
|
|
CN108472298B
(zh)
|
2015-11-24 |
2021-04-20 |
深圳阿拉丁医疗科技有限公司 |
选择性激酶抑制剂
|
|
WO2018041989A1
(en)
|
2016-09-02 |
2018-03-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing and treating refractory celiac disease type 2
|
|
MX394860B
(es)
|
2016-09-27 |
2025-03-24 |
Vertex Pharma |
Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
|
|
US10759865B2
(en)
|
2017-08-22 |
2020-09-01 |
Eyal Levit |
Treatment of diabetes mellitus
|
|
WO2019046316A1
(en)
*
|
2017-08-28 |
2019-03-07 |
Acurastem Inc. |
PIKFYVE KINASE INHIBITORS
|
|
CN108586341B
(zh)
*
|
2018-05-25 |
2020-05-08 |
天津商业大学 |
酰胺类化合物和其药用盐及其制备方法和药物用途
|
|
CA3129665A1
(en)
|
2019-03-21 |
2020-09-24 |
Onxeo |
A dbait molecule in combination with kinase inhibitor for the treatment of cancer
|
|
WO2020201362A2
(en)
|
2019-04-02 |
2020-10-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting and preventing cancer in patients having premalignant lesions
|
|
WO2020212395A1
(en)
|
2019-04-16 |
2020-10-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
|
|
KR20220098759A
(ko)
|
2019-11-08 |
2022-07-12 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
키나제 억제제에 대해 내성을 획득한 암의 치료 방법
|
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
|
CN114605390B
(zh)
*
|
2020-12-04 |
2024-08-16 |
上海凌达生物医药有限公司 |
具有cdk激酶抑制活性的化合物、其药物组合物和用途
|
|
CA3217792A1
(en)
|
2021-05-07 |
2022-11-10 |
Kymera Therapeutics, Inc |
Cdk2 degraders and uses thereof
|
|
US20250283174A1
(en)
|
2022-05-16 |
2025-09-11 |
Institut National de la Santé et de la Recherche Médicale |
Methods for assessing the exhaustion of hematopoietic stem cells induced by chronic inflammation
|
|
WO2026024674A1
(en)
|
2024-07-22 |
2026-01-29 |
Genesis Therapeutics, Inc. |
Methods of treating skp2-associated cancers
|
|
WO2026093435A1
(en)
|
2024-10-31 |
2026-05-07 |
Institut National de la Santé et de la Recherche Médicale |
Use of jak inhibitors for enhancing the potency of immunotherapy in the treament of cancer
|